In support of this notion, combined TIGIT and CD96 blockade has shown increased efficacy at preventing tumor growth via a CD8+ T cell-mediated mechanism in a mouse fibrosarcoma model in comparison to either antibody alone (48). Here, CD96 is linked to neoplasm.